TSVT - 2seventy bio, Inc.
IEX Last Trade
3.05
0 0%
Share volume: 4,323
Last Updated: Thu 26 Dec 2024 08:30:26 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$3.05
0.00
0.00%
Fundamental analysis
9%
Profitability
0%
Dept financing
14%
Liquidity
69%
Performance
3%
Performance
5 Days
1.34%
1 Month
-17.89%
3 Months
-36.34%
6 Months
-15.83%
1 Year
-23.68%
2 Year
-66.45%
Key data
Stock price
$3.05
DAY RANGE
$2.96 - $3.07
52 WEEK RANGE
$3.06 - $6.40
52 WEEK CHANGE
-$33.84
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Nick Leschly
Region: US
Website: 2seventybio.com
Employees: 440
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: 2seventybio.com
Employees: 440
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
2seventy bio, Inc. focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Recent news